|
1
|
Marino N, Woditschka S, Reed LT, Nakayama
J, Mayer M, Wetzel M and Steeg PS: Breast cancer metastasis. Am J
Pathol. 183:1084–1095. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S,
Sun L, Qi Y, Li X and Chen W: Erratum to: RAGE-binding S100A8/A9
promotes the migration and invasion of human breast cancer cells
through actin polymerization and epithelial-mesenchymal transition.
Breast Cancer Res Treat. 156:407–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukherjee D and Zhao J: The Role of
chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer
Res. 3:46–57. 2013.PubMed/NCBI
|
|
4
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
5
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sottoriva A, Verhoeff JJ, Borovski T,
McWeeney SK, Naumov L, Medema JP, Sloot PM and Vermeulen L: Cancer
stem cell tumor model reveals invasive morphology and increased
phenotypical heterogeneity. Cancer Res. 70:46–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawson JC, Blatch GL and Edkins AL: Cancer
stem cells in breast cancer and metastasis. Breast Cancer Res
Treat. 118:241–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li F, Tiede B, Massagué J and Kang Y:
Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res.
17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiozawa Y, Nie B, Pienta KJ, Morgan TM
and Taichman RS: Cancer stem cells and their role in metastasis.
Pharmacol Ther. 138:285–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salmaninejad A, Zamani MR, Pourvahedi M,
Golchehre Z, Hosseini Bereshneh A and Rezaei N: Cancer/testis
antigens: Expression, regulation, tumor invasion, and use in
immunotherapy of cancers. Immunol Invest. 45:619–640. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fratta E, Coral S, Covre A, Parisi G,
Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M: The
biology of cancer testis antigens: Putative function, regulation
and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thomas R, Al-Khadairi G, Roelands J,
Hendrickx W, Dermime S, Bedognetti D and Decock J: NY-ESO-1 based
immunotherapy of cancer: Current perspectives. Front Immunol.
9:9472018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tavakoli Koudehi A, Mahjoubi B, Mirzaei R,
Shabani S and Mahjoubi F: AKAP4, SPAG9 and NY-ESO-1 in iranian
colorectal cancer patients as probable diagnostic and prognostic
biomarkers. Asian Pac J Cancer Prev. 19:463–469. 2018.PubMed/NCBI
|
|
15
|
Sharma P, Gnjatic S, Jungbluth AA,
Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE,
Santiago D, et al: Frequency of NY-ESO-1 and LAGE-1 expression in
bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a
patient with bladder cancer. Cancer Immun. 3:192003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akcakanat A, Kanda T, Koyama Y, Watanabe
M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H and
Hatakeyama K: NY-ESO-1 expression and its serum immunoreactivity in
esophageal cancer. Cancer Chemother Pharmacol. 54:95–100. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Odunsi K, Jungbluth AA, Stockert E, Qian
F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D,
et al: NY-ESO-1 and LAGE-1 cancer-testis antigens are potential
targets for immunotherapy in epithelial ovarian cancer. Cancer Res.
63:6076–6083. 2003.PubMed/NCBI
|
|
18
|
Fossa A, Berner A, Fossa SD, Hernes E,
Gaudernack G and Smeland EB: NY-ESO-1 protein expression and
humoral immune responses in prostate cancer. Prostate. 59:440–447.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raghavendra A, Kalita-de Croft P, Vargas
AC, Smart CE, Simpson PT, Saunus JM and Lakhani SR: Expression of
MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in
triple-negative invasive breast cancers. Histopathology. 73:68–80.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT,
Jungbluth AA, Gnjatic S, Santiago D, Ritter G, Chen WF, et al:
Cancer/testis antigen expression and autologous humoral immunity to
NY-ESO-1 in gastric cancer. Cancer Immun. 4:112004.PubMed/NCBI
|
|
21
|
Aung PP, Liu YC, Ballester LY, Robbins PF,
Rosenberg SA and Lee CC: Expression of New York esophageal squamous
cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol.
45:259–267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cronwright G, Le Blanc K, Götherström C,
Darcy P, Ehnman M and Brodin B: Cancer/testis antigen expression in
human mesenchymal stem cells: Down-regulation of SSX impairs cell
migration and matrix metalloproteinase 2 expression. Cancer Res.
65:2207–2215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yawata T, Nakai E, Park KC, Chihara T,
Kumazawa A, Toyonaga S, Masahira T, Nakabayashi H, Kaji T and
Shimizu K: Enhanced expression of cancer testis antigen genes in
glioma stem cells. Mol Carcinog. 49:532–544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coombes RC, Caballero OL, Shousha S,
Ghaem-Maghami S, Woodley-Barker L, Wilhelm-Benartzi CS and Neville
AM: NY-ESO-1 expression in DCIS: A new predictor of good prognosis.
Oncoscience. 4:33–40. 2017.PubMed/NCBI
|
|
25
|
Hou GX, Liu P, Yang J and Wen S: Mining
expression and prognosis of topoisomerase isoforms in
non-small-cell lung cancer by using Oncomine and Kaplan-Meier
plotter. PLoS One. 12:e1745152017. View Article : Google Scholar
|
|
26
|
Choudhary D, Hegde P, Voznesensky O,
Choudhary S, Kopsiaftis S, Claffey KP, Pilbeam CC and Taylor JA
III: Increased expression of L-selectin (CD62L) in high-grade
urothelial carcinoma: A potential marker for metastatic disease.
Urol Oncol. 33:317–387. 2015. View Article : Google Scholar
|
|
27
|
Ademuyiwa FO, Bshara W, Attwood K,
Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL,
Levine EG, et al: NY-ESO-1 cancer testis antigen demonstrates high
immunogenicity in triple negative breast cancer. PLoS One.
7:e387832012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Theurillat JP, Ingold F, Frei C, Zippelius
A, Varga Z, Seifert B, Chen YT, Jäger D, Knuth A and Moch H:
NY-ESO-1 protein expression in primary breast carcinoma and
metastases: Correlation with CD8+ T-cell and CD79a+
plasmacytic/B-cell infiltration. Int J Cancer. 120:2411–2417. 2017.
View Article : Google Scholar
|
|
29
|
Shao J, Fan W, Ma B and Wu Y: Breast
cancer stem cells expressing different stem cell markers exhibit
distinct biological characteristics. Mol Med Rep. 14:4991–4998.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q,
Song EW and Chen JQ: Pyk2 and Src mediate signaling to
CCL18-induced breast cancer metastasis. J Cell Biochem.
115:596–603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma XJ, Dahiya S, Richardson E, Erlander M
and Sgroi DC: Gene expression profiling of the tumor
microenvironment during breast cancer progression. Breast Cancer
Res. 11:R72009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu H, Patel MR, Prescher JA, Patsialou A,
Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, et al:
Cancer stem cells from human breast tumors are involved in
spontaneous metastases in orthotopic mouse models. Proc Natl Acad
Sci USA. 107:18115–18120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang
Y, Deng J, Margolick JB, Liotta LA, Petricoin E III and Zhang Y:
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer
stem-like cells is required for viability and maintenance. Proc
Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Whitehurst AW: Cause and consequence of
cancer/testis antigen activation in cancer. Annu Rev Pharmacol
Toxicol. 54:251–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
